|
Nonorganic psychosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, these data suggest that a shift towards increased availability (and G-protein coupling) of cortical 5-HT2A vs. mGlu2 receptors may represent a common neurobiological mechanism underlying the emergence of psychosis and cognitive deficits observed in subjects with meth use disorder and schizophrenia.
|
30240581 |
2018 |
|
Nonorganic psychosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pimavanserin is a new 5-HT2A receptor acting drug that has been given market authorization for psychosis in Parkinson׳s disease.
|
27955830 |
2017 |
|
Nonorganic psychosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this review we primarily focus on psychosis in PD, the current treatment possibilities and the new, emerging therapy, pimavanserin, a selective 5-HT2A inverse agonist.
|
27719624 |
2017 |
|
Nonorganic psychosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
5-HT2A inverse agonism, and D3 receptor partial agonism, are now recognized as effective treatments for psychosis.
|
28758583 |
2017 |
|
Nonorganic psychosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
While the hypo-activity of serotonin signaling is involved in the pathogenesis of depression, anxiety and obsessive compulsive disorder; LSD, an agonist of serotonin type 2 receptor (5-HTR2A) induces psychosis.
|
24411530 |
2014 |
|
Nonorganic psychosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
HTR2A gene has been the subject of numerous studies in psychiatric genetics because LSD, which resembles serotonin causes psychosis and atypical antipsychotic drugs target the HTR2A receptor.
|
21550210 |
2011 |
|
Nonorganic psychosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The strong and robust positive association that was noted between the C allele of HTR2A and psychosis suggests that the HTR2A T102C polymorphism is a significant risk factor for psychosis of AD.
|
19910872 |
2009 |
|
Nonorganic psychosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These regulatory changes indicate that the 2AR-mGluR2 complex may be involved in the altered cortical processes of schizophrenia, and this complex is therefore a promising new target for the treatment of psychosis.
|
18297054 |
2008 |
|
Nonorganic psychosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
No significant differences in the distribution of allele and genotype frequencies of the 5-HTTLPR (p>0.01) and 5-HT2A T102C (p>0.05) were found between patients and controls as well as between the patients' subgroups without and with psychosis.
|
17614196 |
2007 |
|
Nonorganic psychosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Parent-of-origin effect and genomic imprinting of the HTR2A receptor gene T102C polymorphism in psychosis.
|
17407792 |
2007 |
|
Nonorganic psychosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Subjects with possible or probable AD or mild cognitive impairment (MCI) without psychosis at study entry were genotyped for the HTR2A T102C polymorphism and reassessed every 6 months until psychosis onset.
|
17525976 |
2007 |
|
Nonorganic psychosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Based on the literature, we hypothesized that the 5-HT2A and 5-HT2C receptor polymorphisms would be associated with agitation/aggression and psychosis and the 5-HTTPR or 5-HTTVNTR polymorphisms, with agitation/aggression or depression and anxiety.
|
15313842 |
2004 |
|
Nonorganic psychosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
No clear association was found between 5-HT2A variants and psychosis.
|
15048655 |
2004 |
|
Nonorganic psychosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Serotoninergic polymorphisms (5-HTTLPR and 5-HT2A): association studies with psychosis in Alzheimer disease.
|
15000807 |
2003 |